90 related articles for article (PubMed ID: 2546724)
1. [Selective resistance of human neuroblastoma cells to a vaccine strain of poliomyelitis virus].
Tol'skaia EA; Kolesnikova MS; Drozdov SG; Agol VI
Dokl Akad Nauk SSSR; 1989; 305(4):987-9. PubMed ID: 2546724
[No Abstract] [Full Text] [Related]
2. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model.
Toyoda H; Yin J; Mueller S; Wimmer E; Cello J
Cancer Res; 2007 Mar; 67(6):2857-64. PubMed ID: 17363609
[TBL] [Abstract][Full Text] [Related]
3. Poliovirus attenuation and pathogenesis in a transgenic mouse model for poliomyelitis.
Racaniello VR; Ren R; Bouchard M
Dev Biol Stand; 1993; 78():109-16. PubMed ID: 8388820
[TBL] [Abstract][Full Text] [Related]
4. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
[TBL] [Abstract][Full Text] [Related]
5. Succession of mutations in the Sabin strain of type 3 poliovirus replicating in the central nervous system of monkeys.
Lu Z; Asher DM; Levenbook IS; Chumakov KM
Virology; 1996 Jun; 220(2):285-9. PubMed ID: 8661379
[TBL] [Abstract][Full Text] [Related]
6. [Studies on the incidence and genetic characteristics of polioviruses during vaccination with polyvalent vaccines].
Jarzqbek Z; Najberg G; Sadowski W
Przegl Epidemiol; 1979; 33(2):277-83. PubMed ID: 225761
[No Abstract] [Full Text] [Related]
7. New assays for the quality control of live oral poliovirus vaccine.
Furesz J; Levenbook I
Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
[TBL] [Abstract][Full Text] [Related]
8. Engineering attenuated virus vaccines by controlling replication fidelity.
Vignuzzi M; Wendt E; Andino R
Nat Med; 2008 Feb; 14(2):154-61. PubMed ID: 18246077
[TBL] [Abstract][Full Text] [Related]
9. Inactivated vaccines based on alternatives to wild-type seed virus.
Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
[No Abstract] [Full Text] [Related]
10. Molecular evolution of oral poliovirus vaccine strains during multiplication in humans and possible implications for global eradication of poliovirus.
Friedrich F
Acta Virol; 2000 Apr; 44(2):109-17. PubMed ID: 10989702
[TBL] [Abstract][Full Text] [Related]
11. Expression of mutated poliovirus receptors in human neuroblastoma cells persistently infected with poliovirus.
Pavio N; Couderc T; Girard S; Sgro JY; Blondel B; Colbère-Garapin F
Virology; 2000 Sep; 274(2):331-42. PubMed ID: 10964776
[TBL] [Abstract][Full Text] [Related]
12. Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice.
Abe S; Ota Y; Koike S; Kurata T; Horie H; Nomura T; Hashizume S; Nomoto A
Virology; 1995 Feb; 206(2):1075-83. PubMed ID: 7856082
[TBL] [Abstract][Full Text] [Related]
13. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
14. When can we stop using oral poliovirus vaccine?
Hull HF; Minor PD
J Infect Dis; 2005 Dec; 192(12):2033-5. PubMed ID: 16288363
[No Abstract] [Full Text] [Related]
15. A deader vaccine?
Minor P
Nat Med; 2008 Feb; 14(2):120-1. PubMed ID: 18256612
[No Abstract] [Full Text] [Related]
16. Studies on new attenuated strains of type III live poliomyelitis vaccine. II. Field trials of Zhong III2 virus.
Chin Med J (Engl); 1980 Sep; 93(9):591-8. PubMed ID: 6253237
[No Abstract] [Full Text] [Related]
17. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.
Minor P
Vaccine; 2009 May; 27(20):2649-52. PubMed ID: 19428874
[TBL] [Abstract][Full Text] [Related]
18. Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.
Burns CC; Shaw J; Campagnoli R; Jorba J; Vincent A; Quay J; Kew O
J Virol; 2006 Apr; 80(7):3259-72. PubMed ID: 16537593
[TBL] [Abstract][Full Text] [Related]
19. Pyrimidine-rich region mutations compensate for a stem-loop V lesion in the 5' noncoding region of poliovirus genomic RNA.
Stewart SR; Semler BL
Virology; 1999 Nov; 264(2):385-97. PubMed ID: 10562500
[TBL] [Abstract][Full Text] [Related]
20. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
